Please login to the form below

Not currently logged in
Email:
Password:

DDR

This page shows the latest DDR news and features for those working in and with pharma, biotech and healthcare.

Evotec spins off cancer tech into new Breakpoint company

Evotec spins off cancer tech into new Breakpoint company

Will challenge AstraZeneca and others in DNA damage response. German biotech Evotec has decided to bundle its cancer therapeutic programmes focused on DNA damage response (DDR) into a new spin-off ... Spinning the programmes into a stand-alone company

Latest news

  • UK biotech Artios Pharma appoints new medical director UK biotech Artios Pharma appoints new medical director

    He will focus on helping Artios progress its pipeline of first-in-class DNA damage response (DDR) therapies. ... The company is developing a next generation of DDR therapies, targeting mechanisms such as the down-regulation or loss of certain DNA repair

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    Baselga also confirmed that it will "highlight an exciting new phase of scientific discovery", in the form of a new wave of DNA Damage Response (DDR) targets. ... Moving its DDR pipeline beyond PARP inhibition, AZ will share data on a potent and

  • DNA damage specialists Artios Pharma raises $84m DNA damage specialists Artios Pharma raises $84m

    We are delighted to work with the management team in building a world class DDR targeted oncology company.”. ... investors for their continued support, which will help us develop and deliver our exciting DDR targeted therapies to cancer patients.

  • Teva signs R&D alliance to pursue novel cancer drugs Teva signs R&D alliance to pursue novel cancer drugs

    Dr Michael Hayden, Teva's chief scientific officer, said: “The alliance provides Teva with the opportunity to research and develop selected and differentiated novel treatments targeting DDR processes.  . ... Teva's multi-project alliance agreement

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    is furthering work in DNA damage response (DDR), a key platform in oncology.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    She says understanding about the role of a host of other DDR pathways and mechanisms is deepening – and AstraZeneca is leading the industry. ... So that’s the rationale behind combinations of DDR agents with immuno-oncology.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Artios Pharma appoints science strategy VP Artios Pharma appoints science strategy VP

    Dr Boulton joins the newly-launched oncology specialist to lead the development of the company's two lead DNA Damage Response (DDR) programmes as well as assisting the business development team ... first-in-class DDR programmes and establish Artios as a

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics